DUBLIN--(BUSINESS WIRE)--The "In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders.
The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector.
Specifically, in 2019, the global R&D spending was estimated to be around USD 182 billion, with over 16,000 drug molecules reported to have been investigated. Presently, the industry is currently under tremendous pressure to identify ways to cope with rising capital requirements in drug discovery research and actively avoid losses owing to failed drug development programs. In addition, there has been an evident increase in regulatory stringency, which has made the drug approval process, especially for large molecules, significantly more difficult.
During the last several years, several computational tools have been developed and introduced for enabling the identification, selection and optimization of pharmacological lead candidates. Currently, there are several in silico approaches available for the drug discovery process alone, such as structure based drug design, fragment based drug discovery and ligand based drug discovery. The predictive power of these in silico tools has been proven to be very advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of large molecule targets.
According to industry experts, almost 35% of the total cost and time invested in developing a new drug can be saved by adopting an in silico approach. As a result, companies offering in silico drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure-activity relationship (QSAR), have now become an important part of the pharmaceutical industry. In future, drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations.
The report features detailed transcripts of discussions held with the following individuals (in alphabetical order):
- John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point)
- Sven Benson (Founder, candidum)
- Mark Whittaker (Senior Vice President, Evotec)
- Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. KEY INSIGHTS
6. COMPANY PROFILES
7. COMPANY COMPETITIVENESS ANALYSIS
8. KEY OPPORTUNITY AREAS
9. EMERGING BUSINESS MODELS AND STRATEGIES
10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES
11. SURVEY ANALYSIS
12. COST SAVING ANALYSIS
13. MARKET FORECAST
14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY
15. EXECUTIVE INSIGHTS
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY
Companies Mentioned
- 16S Technologies
- Ab Studio
- AbbVie
- AbCheck
- Abzena
- Adagio Pharmaceuticals
- Adimab
- Advent International
- Ajinomoto Bio-Pharma
- Allesh Biosciences Labs
- Allosterix Pharmaceuticals
- Ambrx
- AMRI
- Antitope (acquired by Abzena)
- Antiverse
- ApconiX
- Aprecia Pharmaceuticals
- Aptuit
- AsiaVest Partners
- AstraZeneca
- ATHOS Service
- Avistron Chemistry Services
- Bayer Animal Health
- BDG LifeSciences
- BenevolentAI
- Berkeley Lights
- Betta Biomedical Industry Fund
- BIANA
- Bill & Melinda Gates Foundation
- BioAscent
- BioBench Solutions
- Bioclinica
- BioDuro
- BioGlobal Consulting Group
- BioNTech
- Biotech Investment Group
- BIOTEM
- BMG LABTECH
- Broad Institute of MIT and Harvard
- BVCF Management
- Caldan Therapeutics
- CALIXAR
- candidum
- CardioVascular Research Foundation
- CARLBio
- Catalent Pharma Solutions
- And Many Many More Companies!
For more information about this report visit https://www.researchandmarkets.com/r/c1vmn3
